Introduction
Carbohydrates are the most abundantly expressed self-antigens on tumor cells and consequently they are perceived as viable targets for immunotherapy. Aberrant glycosylation of membrane components due to specific alterations of glycosyltransferase activity is a common feature of carcinoma cells and is usually associated with invasion and metastasis. Examples of tumor-associated carbohydrate antigens include GD2, GD3, fucosyl GM1, Globo H, STn and the neolactoseries antigens sialyl-Lewis x (sLex), sialylLewis a (sLea) and Lewis Y (LeY). While pure carbohydrate antigens elicit diminished immune responses because of their T cell independent nature, conjugate vaccine technology has overcome some of these limitations of carbohydrates as vaccines because of the T-dependent (TD) help conferred by the carrier protein. However conjugation of carbohydrates to a carrier protein that elicit carrier-specific T and B cell responses does not necessarily enhance carbohydrate immunogenicity. Furthermore, as there are many carbohydrate types expressed on a tumor cell it may be impractical to develop multivalent vaccines that target each of the surface expressed carbohydrate antigens. Consequently, new formulations or alternative ways to augment carbohydrate immune responses are being evaluated. One alternative that we are pursuing is the development of peptide mimics of core carbohydrate structures expressed on the tumor cell surface. These core structures would be reflective of conformational similarities among what are other wise considered dissimilar carbohydrate antigens. The identification of such peptides would simplify vaccine development in that it may reduce the complexity of multivalent vaccines. Such peptides would function as surrogates of broad-spectrum antigens.
Our studies have evolved to focus on two aspects. One, to better define carbohydrate targets on breast cancer cells that are important in defining their tumor phenotypes and two to develop new formulations or alternative ways to augment carbohydrate reactive immune responses. During the current funding period we have 1.) further examined the murine 4T1 model as a prototype breast cancer cell line defining tumor cell characteristics associated with E and P selectin binding; and 2.) showed that immunization with peptide and DNA form of a rationally chosen peptide mimic, using a lectin reactive profile with 4T1 cells as a template to define carbohydrate types, induces a significant increase in survival rate of tumor-bearing animals in this murine mammary tumor model which is mediated by apoptosis. In the previous year we demonstrated that a peptide mimicking breast associated carbohydrate antigens are capable of activating a carbohydrate specific cellular immune response [Monzavi- Karbassi, 2004 #9] that limits tumor growth in vivo. Thus, carbohydrate-mimicking peptides represent a new and very promising tool to augment immune responses to tumor associated carbohydrate antigens. Task 1. Establish murine breast tumor model (months [1] [2] [3] . The purpose of this task was to develop a model cell line expressing carbohydrate antigens relevant to breast cancer. We chose the 4T1 tumor model based on its tumorgencity, high metastatic potential and similar characteristics with human breast tumors in that 4T1 can metastasize to the lung, brain, liver and bone. However, using monoclonal antibodies FH-6 reactive with dimeric sLex, BR-55 (LeY specific), CA19.9 (sLea specific) and Cslex (sLex specific) in FACS, we established that 4T1 cells do not express epitopes reactive with these antibodies. In order to use 4T1 cells as a relevant breast model for evaluating our mimotopes, we planed to transfect the 4T1 cell line with fucosyltranferases required to generate constituents of neolactoseries antigens in order to express these antigens on the cell surface. During the course of our studies we did come to realize that the 4T1 cell line did expressed a sLex epitope reactive with the monoclonal antibody KM93.
The expression of sLex and sLea by epithelial carcinomas is thought to facilitate metastasis by promoting adhesion of the tumor cells to selectins on vascular endothelial cells. However, experiments supporting this concept by-pass the early steps of the metastatic process employing tumor cells that are injected directly into the blood. While we were developing our model we investigated the relative role of sLex oligosaccharides in dissemination of breast carcinoma, employing the 4T1 spontaneous metastasis model (manuscript #1 submitted). The relative mechanistic roles of selectin ligands in mediating tumor cell dissemination and organ colonization have relied on assessing cells that have been transfected or transduced with genes that affect the expression of E-and P-selectin ligands in experimental metastases models in which tumor cells are injected directly into the blood stream. But selectin ligands might impact earlier steps of the metastatic cascade. It would be advantageous to use a model in which tumor cells are injected into a primary site and tumor cell dissemination and distant organ colonization is then assessed.
The phenotypic properties of a sLex deficient 4T1 mammary tumor-cell subpopulation isolated by negative selection using the sLeX-reactive KM93 monoclonal antibody was explored. Carbohydrate profiling of the tumor cell surface reveals that cells collected by negative selection exhibit considerably modified levels of sialylation and fucosylation. Cells negatively selected do not express sLex and lose E-selectin binding but retain P-selectin binding. In vitro phenotyping of the tumor cells suggests that both KM93-Neg and Pos cells grow at the same rate; however, KM-93Neg cells are able to detach from the primary site and migrate more efficiently to the distant metastatic sites. All mice inoculated in the mammary fat pad with both negatively-and positively-selected 4T1 cell variants produced lung metastases. However, the number of clonogenic lung metastases is significantly increased in the group inoculated with the sLex negative variant (P = 0.0031) indicating that sLex functionally decreased metastatic potential of breast cancer cells in this model. This suggests that the inhibition of tumor cell escape from the primary tumor by sLex expression may have a greater overall effect on metastatic efficiency than promotion of extravasation through adhesion at distal sites.
Producing cell variants First, we examined the binding profile of several monoclonal antibodies against cell surface Lewis antigen-related epitopes known to be important in the metastasis process. Among monoclonal antibodies tested, only KM93 which is directed against sLex reacts with 4T1 cells as assessed by FACS (Table 1 & Fig. IA) . Notably, sLea reactive NS19-9, monoclonal does not react with 4T1 cells (Table 1 & Fig. 1A ). This observation is consistent with early studies that indicate that sLea serves as a ligand associated with cancer cells derived from the lower digestive organs, while the sLex determinant is found to predominate in the adhesion of breast, ovarian and pulmonary cancer cells. The KM93 antibody, reacts with sLex antigen with broad specificity and binding assays indicate that this antigen is abundantly expressed on the surface of 4T1 cells. To study the role of the sLex antigens in the metastasis of the 4T1 cell line, cells were sorted based on two criteria (high binding and low binding) determined via KM93 reactivity, and two segregated subpopulations were consequently produced. These subpopulations were designated as KM93-Pos and KM93-Neg. Following isolation, we tested reactivity of KM93 antibody with the cell variants produced (Fig. 1B) . Experimental results show a non-overlapping peaks in KM93 reactivity between the two subpopulations in FACS analysis. subpopulations.
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Cell sorting could lead to enrichment of minor subpopulations that differ in other cell-surface oligosaccharide structures. The cell surface glycosylation patterns of the subpopulations were determined. We used monoclonal antibodies and a panel of plant lectins to characterize alterations in carbohydrate structures on the cell membrane as illustrated in Table 1 and Figure 2 . ABL (Agaricus bisporus, mushroom, lectin) and ACA (Amaranthus caudatus, lectin) do not react with either the KM93-Pos or KM93-Neg variants indicating that there is no expression of Thomsen-Friedenreich (TF) antigen, Galp3(1--3)GalNAca, or sialylated TF on the cell surface. Consistently, the TF-specific lectin PNA (Arachis hypogaea, peanut, agglutinin) also did not react with either cell subpopulation. VVA (Visia villosa, hairy vetch, agglutinin), which has specificity towards the Tn antigen (GalNAc-a-R), does not distinguish between the cell variants, indicating similar levels of Tn antigen expression. Both GS-I (Griffonia simplicifolia) and SNA (Sambucus nigra, agglutinin), which are specific for the a-Gal epitope and cc(2---6) sialic acid, respectively, react identica lly with both subpopulations. ECL (Erythrina critagali, lectin) shows a slight increase in reactivity with the KM93-Pos variant and is specific for Galp3(1--4)GlcNAc, suggesting that positive selection for the KM93 epitope exposed more type II chain LacNAc, a major component of most N-linked structures including sLex.
As shown in Figure 2 , WGA (Wheat germ agglutinin), which is specific for both GlcNAc and sialic acid, shows a significant increase in binding to the KM93-Pos cells suggesting elevated levels of either one or both of these structures. To distinguish between GlcNAc and sialic acid, we tested the binding of succinalated WGA (Table 1) , which binds to only GlcNAc residues and not sialic acid. Succinylated WGA did not differentiate significantly between the two subpopulations, implying that the higher WGA binding to the positive variant is most likely due to an increased level of terminal sialic acid. The decrease in sialic acid on the surface of the KM93-Neg variant is most likely that of the cc(2--3) linkage type (comparison of SNA binding vs. WGA binding between the two variants). Ulex europaeus (UEA-I) lectin, which reacts mostly with terminal a(1--2) linked fucose residues 35, was also tested for binding (Fig. 2) and displayed significantly higher reactivity with the KM93-Pos variant. Taken together, the lectin binding profile suggests that negative selection for the KM-93 reactive epitope has resulted in a decrease in sialic acid and of terminal ct(1--2) mono-fucosylated structures. Monoclonal antibodies to Lewis x (Lex, BRA-4F1), sialylated dimeric Lewis x (FH6) and sLea (NS19-9) did not show reactivity with 4T1 cells or its variants (Table 1) . Based on data obtained from GS-I binding, we believe that chain termination in the KM93-negative population has not been replaced with either sialic acid or aGal. Since UEA is specific for a(1-2) monofucosylated structures but not further modified by glysosylation such as difucosylated LeY structure or blood group A and B structures we can not conclusively conclude whether al,2 fucosyltransferase is responsible for decreased expression of SA-Lex. To corroborate the above observation, NMR spectroscopy was employed to further characterize cell surface glycan structures. 'H NMR spectra of intact cells confirmed a decrease in cell surface sialic acid (1.91 ppm) in KM93-Neg cells, corroborating the WGA lectin binding data ( Figure 3A) . In KM93-Pos cells, the fucose resonance at 1.2-1.3 ppm is more clearly observable than that in the KM93-Neg ( Figure  3B ). In addition to the compounds mentioned, a spectral pattern comprised of major resonances at 0.63 ppm, 1.75 ppm, and 2.9 ppm all showing connectivities to one another (verified by COSY spectra 36 is also observable on the surface of KM93-Neg cells yet is either diminished or completely absent from the surface of KM93-Pos cells (Figure 3 ). Together these results indicate that the KM93 positive and negative variants have distinct cell surface glycosylation patterns. The loss in KM93 reactivity toward sLex may result from a loss of sialic acid residues from the KM93 reactive carbohydrate epitope. Reactivity of cell variants with E-and P-selectin chimeric proteins Murine 4T1 is a highly metastatic cell line, and based on its reactivity with KM-93 mAb, the expression of E-or P-selectin ligand(s) on its surface is expected. To investigate the functional significance of the different cell surface carbohydrate expression patterns, the cells were tested for binding to E-and P-selectin. To determine whether P-and E-selectin molecules react differently with the cell variants, cells were incubated with recombinant mouse E-and P-selectin/Fc (human IgG) chimeras and binding was assayed by flow cytometry. As shown in Figure 4 , E-selectin bound weakly to the original 4T1 cells and it's binding increased after positive selection for KM93 reactive epitope. E-selectin did not bind to the KM93-Neg variant. Reactivity of P-selectin with selected variants remains similar to the levels detected in binding to the parental 4T1 cells. These results indicate that binding of E-selectin to the 4T1 cells correlate with the expression level of its ligand sLex. These results further indicate that negative selection resulted in a cell line deficient in the biosynthesis of E-selectin ligands that may include sLex as other cell variants lacking sLex expression still retain E-selectin binding. Tumor cell adhesion to HUVEC cells. To further clarify the binding properties of the cell variants, monolayer of HUVECs were prepared and adhesion of the parental 4T1 and other selected cell variants to them was determined (Fig. 5 ). Binding of parental 4T1 cells and its variants to HUVECs was increased between 60 to 100% after TNF-cc treatment, however, no significant differences in adhesion after treatment with TNF-a among the cell types was observed (data not shown). TNF-a treatment has increased the expression of E-seletin more than 100 times as assayed by flow cytometry (data not shown). Data imply that binding to endothelial cells might not be affected by either the positive or negative selections for the KM93 epitope. Invasive ability and apoptosis sensitivity of tumor cells To further explore and compare relevant characteristics among cell variants, we performed Matrigel T m -based invasion assay and an apoptosis related assay to see if the selection has changed sensitivity of cells to apoptosis or their invasive ability. We did not observe significant differences between cell variants regarding their ability to invade MatrigelTm or their sensitivity to starvation-induced apoptosis (data not shown).
4T1
In vitro growth characteristics of cell variants
Comparison of cell growth in vitro revealed a similar growth rate for both KM93-Neg and -Pos subpopulations (Fig. 6A) ; however, the growth pattern is different ( Figure  6B ). The KM93-Pos variant, which is similar to the original 4T1, tends to grow in clusters with high densities. While clusters are also visible in the KM93-Neg variant, this cell type has a tendency to spread out individually and quickly on the plate surface. Shortly after seeding the cells in vitro, KM93-Neg cells was observed to scatter, covering the surface, while KM93-Pos cells grew in separated clusters with surface void volume in between. To evaluate the rate of migration, we conducted a wound healing experiment (Fig. 6C ). As illustrated, 24 hours after scraping KM93-Neg cells begin to cover the scraped surface on the dish, and at 48 hours later the progress is obvious. In the same time frame, KM93-Pos cells have yet to form separate colonies on the bare surface. These results suggest that selection for the carbohydrate epitope significantly changed the in vitro adhesion properties of the cells. A) The same number of cells (5000/welll) was seeded in wells of a 96-well plate at the day zero and cell proliferation was assessed using NITS assay as described in materials and methods. Bars show SD of three replications. B) Wells were photographed on days 2, 3 and 4 and representative images are shown. C) The same number of cells was seeded into 100mm tissue culture plates and when the cells were grown to confluent state, the cell layer was scraped in the middle of the plate. Photographs were taken at the time of scraping, 24 hours and 48 hours later as indicated.
Tumor growth and metastasis in vivo. sLex on the surface of tumor cells is thought to promote metastasis by enhancing adhesion of tumor cells to endothelia in the vascular beds of distal organs. This in turn is thought to facilitate extravasation of the tumor cells and promote establishment of metastases. Much of the evidence supporting the role of sLex in the late stages of metastasis is derived from experimental animal models where the tumor cells are introduced directly into the peripheral blood. In these models, the tumor cells by pass all of the early barriers to metastasis that tumor cells arising in the breast or other tissues of origin must successfully negotiate 4. Here we investigated possible differences in spontaneous metastasis using a mouse model that requires tumor cells to go through all steps of the metastatic process. Tumor transplantation with the cell variants was performed to evaluate their metastatic tendency. Groups of mice were inoculated with both the positively-and negatively-selected subpopulations to compare tumor growth and metastasis (Fig. 7) . We observed a statistically significant (P = 0.0031) higher number of established metastatic cells in the lung for KM93-Neg cells (Fig. 7A ). Metastatic disease, mainly to the lungs, liver, bone, and brain, is the most common cause of death from breast cancer. Induction of a systemic immune response to common tumor-associated antigens (TAA) is proposed as a general approach to eradicate metastatic lesions. Tumor cells, however, escape an ongoing immune response using various mechanisms including loss of target antigen and down regulation of MHC molecules or disruption of complement cascade. Therefore, employing novel anti-tumor immunological mechanisms in the immunotherapy array are needed. Apoptosis is a natural anti-tumor weaponry used by the organism to arrest growth of transformed cells. Natural carbohydrate reactive IgM antibodies are implicated in mediating apoptosis of tumor cells and these circulating natural antibodies are suggested as a mechanism of innate immune surveillance against cancer cells. The selective targeting of tumor associated carbohydrate antigens by induction of serum antibodies that trigger apoptosis as a means to eradicate tumor cells would therefore be an advantage in vaccine development (manuscript #2 submitted).
Choice of peptide mimotope
Arrays of peptide mimotopes have been developed in our Laboratory over the years. We screened several of them for binding to the lectin GS-1 that is reactive with the murine Gal epitope and with the human antigens Leb and LeY. Peptide mimotopes shown in Table 2 were screened for reactivity against GS-1. We observed that GS-1 binds predominately to peptides 107 and 105 (manuscript # 2 submitted). We observed that only peptide 107 bound to GS-1 in a dose-dependent manner. In an inhibition assay, the peptide 107 significantly inhibited GS-1 lectin binding to the cells. The 107 peptide was chosen for our studies based on its consistent reactivity with GS-1 (manuscript #2 submitted). Previous studies have indicated that immunization with this peptide produce serum antibodies able to mediate complement dependent cytotoxicity on Meth A and MCF7 cells, which inhibited Meth A cell growth in vivo.
DNA Immunization results in induction of serum antibodies reactive with 4T1 cells
We have previously shown that immunization with peptide mimotopes of carbohydrate antigens formulated as multiple antigen peptides or as DNA vaccines can elicit carbohydrate reactive IgM serum antibodies. To expand this later strategy, the sequence of peptide 107 was translated into oligonucleotides and DNA constructs were developed in a secretory (pSec) plasmid from Invitrogen (Manuscript # 2 submitted). Groups of mice were immunized with the 107-peptide-encoding DNA constructs and serum reactivity with 4T1 cells was detected by FACS (Fig. 8) . We detected anti-4Tl-cells serum antibodies of IgM isotype, with no cell-specific IgG isotype detected. Serum antibodies mediated cell death upon Co-incubation with 4T1 cells. In order to assess serum-mediated cell cytotoxicity, cells were co-incubated with serum from peptide encoded DNA-or vector-alone immunized mice and the percentage of dead cells was detected after overnight co-incubation. We observed 20% dead cells in wells containing 107-pSec serum in comparison with wells supplemented with vector-immunized serum. In concert with the GS-I effect, immunization-generated serum mediated apoptosis of 4T1 cells (Fig. 9 ). DNA immnization was next compared with peptide immunization. Mice were bled 7 days after the third immunization. Serum was collected individually and all sera were pooled for 10 mice in each group. Binding of pooled serum to 4T1 cells and its apoptotic activity was assayed ( Table 3) . As shown in the Table 3 immunization with both peptide and DNA formulated vaccines generates serum antibodies that bind to 4T1 cells and mediate apoptosis of this cell line. The Peptide formulated vaccine .
-immunii-zaitin--geiei&rates--anif bo-di& 6f iigher-e-d p6int titer, which mediated a more pronounced apoptotic effects. To further explore and compare pathways involved governing observed apoptotic effects, we examined activation of caspase 2, 3, 8 and 9 in 4T1 cells after treatment with the lectin and the serum from peptide 107 immunized mice (Table 4) . Overnight incubation with the GS-I lectin induced activation of all caspases tested. Further experiments were performed to identify the first caspase activated. As shown in Table 4 , after 4 and 6 hours of co-incubation with the lectin, caspase 3 followed by caspase 2 are the first caspases that could be detected. We also tested activation of the same caspases after coincubation of cells with the serum overnight. We detected activation of all caspases after over night incubation of cells with serum from 107-immunized mice but not with sera from peptide 106-immunized or naYve mice (data not shown). Further, when we compared the level of activation of caspases at 4 and 24 hours of co-incubation with the peptide 107 derived serum (Table 4) , we observe that similar to the lectin, Caspase 3 and Caspase 2 act as the major players in mediating apoptosis of 4T1 cell. The murine 4T1 breast tumor cell line is a highly metastatic mammary cell line proposed to model metastatic disease in advanced stages metastasizing efficiently to lung, liver, bone and brain after implanting into mammary fat pads and has proven to be weakly immunogenic and highly aggressive. This animal model closely resembles human breast cancer and is a rigorous model of advanced spontaneous metastatic disease. Clonogenic lesions are first detected in the lung and then liver in a time .dependent manner. Lung metastasis is detectable as early as day 14 after transplantation in all mice tested while for liver, this time is around day 28-35 after transplant (Table 5) To further characterize the effects of immunization on metastasis to distant organs, we repeated the challenge experiment as above and 30 days post tumor transplant, lung and liver samples were harvested and metastatic lesions were quantified ( Table 6 ). The immunization regime had no effect on the lung metastasis but had significant positive effects on reducing liver metastasis (Fisher exact test, p = 0.0 18). Out of 12 mice used for 107 therapeutic DNA immunization only 2 were found positive for tumor in the liver compared with 8 out of 12 positive livers in vector immunized animals. Prophylactic immunization with DNA and the peptide Therapeutic immunization had no significant effect either on the size of primary tumor or on lung metastasis. This might be because of the late appearance of antibodies in adequate concentration. To test whether or not earlier immunization and accumulation of antibodies at the time of tumor challenge modify the outcome of immunization, in a follow-up study mice were immunized before the challenge and after that with both the peptide and DNA constructs. Mice were bled 7 days after the third prophylactic immunization and then challenged with 4T1 cells 3 days after the blood collect. In both peptide and DNA-immunized animals tumor grew significantly slower. All preimmunized mice developed tumor upon challenge, however, tumor growth was significantly slower in peptide 107-immunized animals (Fig. 10) . We have not observed tumor growth inhibition in our therapeutic immunization regimen. Others have shown that the size of solid primary tumor in this model correlates with the number of established metastatic cells in the lung. We collected lungs at day 28 post tumor transplant from both DNA and peptide immunized mice and performed clonogenic assay.. . In the peptid-eirimuiiiiedgruip (with 10 mice per group), 30 percent of 107-peptide immunized animals were detected as free of lung tumor. In addition, comparison of the average of clonogenic lung metastases showed a significant reduction in the 107-immunized group (Fig 10C) . In the DNA-immunized group all mice tested had established lung metastasis, however, pSec-107 immunized mice had smaller average of colonies than pSec-106 and pSec vector control (data not shown). antigen and the anti-serum binding to Leb was abrogated by serial pre-adsorption with both LeY and Leb (Fig. 11) . This result implies that the antigen is a common constituent of both antigens meaning that whatever happens in the mouse model might happen in human. We also screened peptides 105, 106, 107 and LeY with human serum from normal patients and Breast cancer patients (n=10). We observed that peptides 106 and 105 were more reactive with serum from Breast Cancer patients over serum from normal patients (controls) out to about 1:800 titer. This distinction was not observed for peptide 107 (data not shown) which maybe explained if we think peptide 107 is a mimic of the Gal epitope in which 1% of total circulating IgG is reactive with. We are presently pursuing the screening of peptide 107, 106 and 105 against a human single chain antibody library to test if identified antibodies can mediate the apoptosis of tumor cells. In addition, we are examining archived tissue slides for staining with GS-1. In very preliminary studies we observed a marked restriction in GS-1 histology stains to tumor cells of breast and ovarian origin. This work is finalizing the rationale of moving forward with peptides 107 and 106 into the clinic in the coming year in Phase I.
Key research accomplishments 1. We characterized the carbohydrate profile of 4T1 cell surface and observed that KM-93, and GS-1 bind to 4T1 cells. 2. We observed that transfection with Fut 3 changes the expression profile of E selectin reactivity. Cells negatively selected for reactivity with KM93 do not express E selectin ligands. This is first time a cell line has been defined that selectively expresses P selectin ligands and opens up many avenues of research examining the properties of these ligands in a spontaneous model of metastases. 3. We defined potential peptide mimotopes for targeting 4T1 cells in vivo. Based on the screening of our mimotopes against the GS-1 we chose peptides that most likely mimic carbohydrate epitopes on the surface of the 4T 1 cells. 4. We observed that immunization with DNA induced IgM antibodies reactive with 4T1 cells. The sequences of peptide mimotopes were converted to DNA and cloned in a vector that secrets coded peptides. Immunization with constructed plasmids induced IgM antibodies against Leb and leY antigen found on human breast cells, and a murine epitope found on murine 4T1 cells.
5.
We observed that DNA administration of 4Tl-tumor bearing animal temporarily reduces the burden of tumor. Mice were inoculated with tumor cells and 3-4 days after transplant therapeutic immunization was started with DNA constructs. A temporary shrinkage of tumor mass was observed in the group immunized with the construct encoding 107 peptide. 6. DNA administration of the 107 peptide significantly increases survival rate of animals. Survival experiments showed that immunization of tumor-bearing animals significantly increases survival rates. 7. We observed that administration of 107 DNA inhibits liver metastases. Two weeks after the completing of the immunization, mice were sacrificed, organs were harvested and distant-site metastases was measured by clonogenic assay.
Reportable outcome. One manuscript has been published, and two more submitted. . binding site (7, 8) . Crystal structure analysis of T-cell receptor binding Immunization. As in our previous studies (11, 12), peptide 106, having the to model glycopeptides has indeed shown that T cells can recognize sequence GGIYWRYDIYWRYDIYWRYD, was synthesized as a multipleGIcNAc-linked glycopeptides bound by the MHC molecule (9, 10). T antigen peptide (Research Genetics, Huntsville, AL). Each mouse received 100 cells, therefore, have the potential to react with the GIcNAc moiety of Axg of 106 multiple-antigen peptide and 20 ;Ig of QS-21 (Antigenics Inc., glycopeptide antigens, suggesting that T cells can target to presented Framingham, MA) i.p., both resuspended in 100 tl of PBS three times at 5-day carbohydrate antigens on tumor cells, intervals. Recombinant murine interleukin (IL)-12 (Sigma, St. Louis, MO) was In an effort to further define strategies to augment immune readministered i.p. once daily for 5 days, starting on the day of the last peptide sponses to tumor cells, we have been developing peptide mimics of immunization, Flow Cytometry. Acquisition and analysis were performed as described tumor-associated carbohydrate antigens and have demonstrated t earlier (12) . Cells were resuspended in a buffer containing, Dulbecco's PBS, peptides synthesized as multivalent peptides can emulate or mimic the 1% BSA, and 0.1% sodium azide and incubated with biotinylated peanut native clustering or presentation of tumor cell-displayed carbohydrate agglutinin or WGA (10 /rg/ml; Vector laboratories, Burlingame, CA) for 30 antigens (11). We have shown that prophylactic vaccination with a min on ice. Cells were then stained with FITC-conjugated streptavidin at 1:500 peptide surrogate, having the sequence GGIYWRYDIYWRYDIYdilution for another 30 min on ice. WRYD (and referred to as peptide 106), induces a tumor-specific ELISA and Inhibition Assays. ELISA was performed as described prehumoral response inhibiting tumor growth of a methylcholanthreneviously (11). Briefly, plates were coated with 106 multiple-antigen peptide. induced sarcoma cell line (Meth A) in vivo (11). This peptide also Biotinylated WGA was added, and binding was visualized with streptavidin-horseradish peroxidase (Sigma, St. Louis, MO). Absorbance was read, using a Bio-Tek ELISA reader (Bio-Tek instruments, Inc, Highland Park, Received 5/28/03; revised 10/2/03; accepted 1/7/04. Vermont). For inhibition assay, GlcNAe and N-aeetylgalaetosamine, atGrant support: NIH Grant CA089480 and Department of Defense Grant DAMDI7-0101-0366.
tached to a polyacrylamide polymer (GlycoTech Corporation, Rockville, The costs of publication of this article were defrayed in part by the payment of page MA), were used as carbohydrate competitor. Biotinylated WGA (2.5 p.g/ charges. This article must therefore be hereby marked advertisement in accordance with ml) combined with serial concentrations of carbohydrates and incubated 18 U.S.C. Section 1734 solely to indicate this fact.
overnight at +4°C. T-Cell Purification. Splenocytes were harvested from spleens and prepared by lysis of erythrocytes and consequent washing several times with fresh medium (12) . Splenocytes were first passed through nylon wool and then,"K." using MiniMACS (Miltenyi Biotec, Auburn, CA), natural killer cells were , depleted using anti-natural killer cell (DX5) microbeads. (Fig. 1, A and B) . WGA binds to the peptide 106 mimotope Nac) was used as a negative control. WGA was preincubated with serial dilutions of in a concentration-dependent manner as assessed by ELISA (Fig. IC) . carbohydrates overnight at +4°C and then added to peptide-coated plates as above. This binding is selectively and significantly inhibitible by WGA-Results present the mean value ± SD. *, P < 0.05; **, P < 0.01. *** P < 0.0005, as reactive GlcNAc in a concentration-dependent manner (Fig. ID) , compared with the inhibition of GalNac at the same concentration. further indicating that the peptide mimotope is reactive with the GlcNAc-binding site of WGA, and, therefore, peptide 106 is an highly effective even at lower doses of IL-12, because 100 ng of daily effective antigenic mimic of GlcNAc. IL-12 treatment in the combined therapy, but not alone (X 2 test, Therapeutic Peptide Immunization Induces Tumor Regression. P = 001), eradicated tumors in five mice of five challenged (Fig. 3 , To study the outcome of peptide immunization on the growth of solid A and B). The time of the beginning of immunization and the size of tumors in vivo, we evaluated the antitumor effect of the peptide 106 tumor at the time of immunization affect the efficacy of immunizaon established Meth A tumors. BALB/c females were inoculated s.c. tion. When immunizations were started at day 14 or later or when with Meth A cells, and 7 days later, treatment was started with the treating tumors with a mean diameter larger than 7 mm, the efficacy peptide. As shown in Fig. 2 .A, immunization moderately affected the of immunization dropped (Fig. 3C) , ruling out the possible effect of growth of Meth A sarcoma, because 6 mice of 11 immunized were hyperimmunization per se on the outcome of the challenge expericured (X 2 test, P = 0.01, as compared with animals that were given ments. To further rule out nonspecific effects of hyperimmunization, IL-12 only). Fig. 2B demonstrates that treatment of animals with we observed that cell-based vaccination using 106 mitomycin-C-IL-12 after peptide immunization tended to enhance the immune inactivated Meth A cells, followed by IL-12 administration, also response and was successful in mediating complete eradication of failed to induce tumor regression (Fig. 3D) . This latter result conestablished tumors (2 test, P = 0.008, as compared with peptide-firmed a previous study in which Meth A immunization along with immunized only). Treatment of tumor-bearing mice with only IL-12 IL-12 failed to induce tumor regression (14) . Our results are in did not affect tumor growth (Fig. 2C ) in keeping with other such agreement with other therapeutic vaccine studies on Meth A cells, in studies (14) .
which enhancement of antitumor T-cell responses led to quick eradWe further determined that peptide/IL-12 combination therapy is ication of established tumors (15, 16). Adoptive Transfer of Splenocytes Stimulates Eradication of to tumor-bearing nude mice. Our data indicate that CD8+ cells are Tumors in Nude Mice. To further assess whether the antitumor required for efficient eradication of tumor; however, the process activity mediated by peptide/IL-12 therapy is T-cell dependent, we seems dependent on both CD4+ and CD8+ cells (Fig. 5) . Histologevaluated our therapeutic strategy in nude mice. BALB/c-nulnu mice ical sections of tumor sites and surrounding tissues were prepared bearing Meth A tumors were immunized with the peptide followed by (Fig. 6 ). Contrary to nonimmunized tumor-bearing mice, we detected IL-12 treatment. Combined peptide/IL-12 therapy had no effect on lymphocytes around the periphery and infiltrating into tumor mass of tumor growth of nude mice, indicating the dependence of mediated immunized mice (Fig. 6, A and B) . Staining of sections obtained from tumor regression on T cells (data not shown). Next, nude mice were the tumor site of a cured mouse shows the presence of lymphocytes, transplanted with Meth A cells and were give injections i.p. of fresh although no tumor is detectable microscopically (Fig. 6C) . splenocytes, isolated from cured mice, 10 days later (Fig. 4 ). Immune cells transferred had a dramatic effect on tumor size because by day 15 after transfer, tumor was eradicated completely in all four mice DISCUSSION tested (X 2 test, P = 0.005).
In a follow-up study, splenocytes were depleted of B cells and Carbohydrates are abundantly expressed on the surface of maligenriched for CD4+ or CD8+ cells, in vitro, and then were transferred nant cells, and induction and enhancement of a cell-mediated immune response toward these antigens has outstanding implications in vaccination for and treatment of cancer. T-cell recognition of nonpeptidic
A B
and modified peptide antigens is, however, still poorly understood. Because resting T cells do not express the IL-12 receptor (19) and studies. Because IL-12 responsiveness of T cells is induced after IL-12 responsiveness is only activated after T-cell receptor stimula-T-cell receptor stimulation, the lack ofIL-12 responsiveness suggests tion (20) , we observed that purified peptide-specific T cells were that T cells in Meth A-bearing mice are not sensitized to Meth A stimulated with IL-12 in vitro (data not shown). IL-12 treatment is tumor antigen on immunization with Meth A cells. In contrast, our ineffective in the Meth A tumor model (14) as further observed in our data suggest that peptide immunization can sensitize tumor-reactive T cells that are responsive to IL-12. It is possible that peptide immunization further expands B and T cells that have been primed via shed E25 -CD4 glycoprotein(s) processing. We propose that peptide 106 immuniza-E tion activated a population ofThl and CTLs with production of IFN-y C 20 (12) , and in vivo IL-12 treatment further helps to expand the T-cell population and IFNy production. In previous studies, the failure of E 1S-IL-12 treatment to induce tumor regression was also considered to be Results present the mean value ± SD. *, P < 0.05; **, P < 0.01. ***, P < 0.0005, as moieties on native glycopeptides (21) . Peptides that mimic carbohycompared with mean tumor diameter of CD4+ -transferred animals.
drate structures attached to class I or class II anchoring peptides would
